Product Information Sheet for NR-2759

Influenza A Virus, A/WS/33 (H1N1) (Tissue-culture adapted)

Catalog No. NR-2759

(Derived from ATCC® VR-1520™)

For research use only. Not for human use.

Contributor:

ATCC®

Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus A*
Species: Influenza A virus
Strain/Isolate: A/WS/33 (H1N1) [A/Wilson-Smith/33 (H1N1)] (tissue-culture adapted)
Source: Derived from ATCC® VR-1520™. ATCC® VR-1520™ was derived through tissue culture adaptation of ATCC® 825™, which was isolated in 1933 from throat washings of a patient with influenza.[1]
Comments: Influenza A virus, A/WS/33 (H1N1) was deposited at ATCC® by W. Adrian Chappell, Ph.D. The complete genomic sequence of influenza A/WS/33 (H1N1) has been submitted (GenBank: CY009604 to CY009611).[2]

Influenza A virus, A/WS/33 (H1N1) is the first human isolate of influenza virus and considered to have descended from the strain responsible for the 1918 pandemic.[3]

Material Provided:

Each vial contains approximately 1 mL of cell lysate and supernatant from Madin-Darby canine kidney cells (MDCK; ATCC® CCL-34™) infected with influenza A virus, A/WS/33 (H1N1) (tissue-culture adapted).

Note: If homogeneity is required for your intended use, please plaque-purify prior to initiating work.

Packaging/Storage:

NR-2759 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: MDCK cells (ATCC® CCL-34™)
Growth Medium: Minimum Essential Medium supplemented with 1 µg/mL TPCK-treated trypsin and 0.125% Bovine Serum Albumin, or equivalent (lot-specific details are on the Certificate of Analysis)
Infection: Cells should be 80–90% confluent (not 100% confluent)
Incubation: 3 to 5 days at 33°C to 35°C and 5% CO_2
Cytopathic Effect: Cell rounding and detachment

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Influenza A Virus, A/WS/33 (H1N1) (Tissue-culture adapted), NR-2759."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Smith, W., et al. "A Virus Obtained from Influenza Patients." Lancet 2 (1933): 66–68.
2. Ghedin, E., et al. "The NIAID Influenza Genome

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

Sequencing Project." Direct submission (2006).
3. Zambon, M. C. "The Pathogenesis of Influenza in Humans." Rev. Med. Virol. 11 (2001): 227–241. PubMed: 11479929.
4. Hoffman, E., et al. "Universal Primer Set for the Full-length Amplification of All Influenza A Viruses." Arch. Virol. 146 (2001): 2275–2289. PubMed: 11811679.
5. Ward, A. C. "Changes in the Neuraminidase of Neurovirulent Influenza Virus Strains." Virus Genes 10 (1995): 253–260. PubMed: 8560787.
6. Ward, A. C., et al. "Complete Nucleotide Sequence of the Non-structural Gene of the Human Influenza Virus Strain A/WS/33." Nucleic Acids Res. 21 (1993): 2257. PubMed: 8502573.
7. Burnet, F. M. "A Genetic Approach to Variation in Influenza Viruses; the Characters of Three Substrains of Influenza Virus A (WS)." J. Gen. Microbiol. 5 (1951): 46–53. PubMed: 14824469.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org